FDA nod for generic Lialda launch to boost US biz for Zydus Cadila in FY18
Market for the drug, which could be a key growth driver for firm's US business, is pegged at $1.1 bn07-06-2017
07-06-2017
Cadila Healthcare hits fresh 52-week high
Shares of Cadila Healthcare hit their fresh 52-week high in early trade on Tuesday.06-06-2017
Zydus Cadila gets USFDA nod for anti-depressant
Drug firm Zydus Cadila has received the US Food and Drug Administration 's nod to market Mirtazapine, an anti-depressant, in the American market05-06-2017
Cadila's US business hopes soar on Moraiya plant approval
The US market contributes around 40% to the company's revenues02-06-2017
Zydus Cadila gets USFDA nod for generic epilepsy drug
Zydus Cadila has received approval from US health regulator to market Felbamate tablets, used to treat seizures in people with epilepsy, in the American market. The company has received approval...31-05-2017